Antibodies to ntb-a

Abstract

Anti-NTB-A antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind NTB-A and treat diseases, such as hematologic malignancies, which are characterized by expression of NTB-A.

1 . An isolated protein that specifically binds NTB-A antibody, comprising:
 a) three CDRs from a heavy chain, comprising; and   b) three CDRs from a light chain, wherein the protein is chimeric, humanized, an Fab antibody, or Fab′ antibody, or an (Fab′)2 antibody, or a single chain antibody.   
     
     
         2 .- 74 . (canceled) 
     
     
         75 . The isolated polypeptide of  claim 1 , wherein the CDRs are SEQ ID NOs: 30, 31, 32, 33, 34, and 35. 
     
     
         76 . The isolated polypeptide of  claim 1 , wherein the CDRs are SEQ ID NOs: 24, 25, 26, 27, 28, and 29. 
     
     
         77 . A method of recombinantly producing antibody or antibody fragment that specifically binds NTB-A comprising expressing the antibody from a host cell containing an exogenous nucleic acid sequence encoding the antibody, wherein the antibody comprises three CDRs from a light chain of an antibody or three CDRs from a heavy chain of an NTB-A antibody. 
     
     
         78 . The method of  claim 77 , wherein the CDRs are SEQ ID NOs: 30, 31, 32, 33, 34, and 35. 
     
     
         79 . The method of  claim 77 , wherein the CDRs are SEQ ID NOs: 24, 25, 26, 27, 28, and 29. 
     
     
         80 . The method of  claim 77 , wherein the antibody is chimeric. 
     
     
         81 . The method of  claim 77 , wherein the antibody is humanized. 
     
     
         82 . The method of  claim 77 , further comprising isolating the antibody.